S&N gains exclusive rights to Acticoat dressing in $21m buy
This article was originally published in Clinica
Smith & Nephew’s advanced wound management subsidiary has gained full control of the Acticoat antimicrobial barrier dressings range after the firm purchased the product’s manufacturer Nucryst Pharmaceuticals. Previously, S&N exclusively licensed the product from Nucryst. As part of the acquisition, S&N will acquire Nucryst’s Fort Saskatchewan, Canada-based operations and intellectual property related to the dressing for $21m. The Acticoat dressing utilises Nucryst’s Silcryst nanocrystalline silver coating technology and offers bacterial reduction, fluid management and sustained release of silver ions. It has a non-adherent design. Nucryst ran into trouble earlier this year when it received a notice from the Nasdaq that it was not in compliance with the exchange’s rules after it had traded at below $1.00 per share for more than 30 days.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals